Source: International Congress 2016 – Features and impact of comorbidities in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Kateryna Gashynova (Dniepropetrovsk, Ukraine), Kateryna Gashynova. COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability. Eur Respir J 2016; 48: Suppl. 60, 652

Member's Comments

No comment yet.

Related content which might interest you: Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level Source: Annual Congress 2013 –COPD mechanisms Year: 2013 LSC - 2019 - Plasma surfactant protein-D (SP-D) as a predictor of COPD severe acute exacerbation (SAE) Source: International Congress 2019 – Exacerbations of airway diseases Year: 2019 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 Plasma surfactant protein-D (SPD) concentration and severity of airflow limitation in COPD patients (pts) Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Neutrophil/lymphocyte (NLR) ratio in infectious acute exacerbations of COPD (AECOPD) Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014 Co-morbidity and hospitalization rate in patients (pts) with acute exacerbation (AE) of COPD Source: International Congress 2015 – Different data in COPD Year: 2015 Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation Source: International Congress 2016 – Inflammatory biomarkers in airway diseases Year: 2016 BNP level in patients with COPD exacerbations Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 The role of biomarkers in predicting outcomes in acute exacerbations of chronic obstructive pulmonary disease (AECOPD) Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU Year: 2013 CAT in COPD phenotypes (POPE study) Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Vascular-platelet hemostasis parameters in the stable phase and in acute exacerbation (AE) of COPD Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015 Midrange-proadrenomedullin in stable state predicts severe exacerbation of COPD Source: International Congress 2016 – Exploring mechanisms in health and disease Year: 2016 The prognostic value of cardiac and inflammatory biomarkers in acute exacerbations of COPD Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Plasma surfactant protein D (SP-D) and comorbidity rate in patients with COPD Source: International Congress 2014 – Predictors Year: 2014 Neutrophil CD 64 expression as a diagnostic marker of pneumonia in patients with acute COPD exacerbation Source: International Congress 2014 – Markers Year: 2014 Role of inflammatory biomarkers in COPD Source: International Congress 2016 – Systemic biomarkers Year: 2016 Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016